In a retrospective study, researchers found that the combination of insulin and oral glimepiride (sulphonylureas) in patients with T2D showed a more significant improvement in HbA1c control compared to insulin alone, decreasing from 8.5 +/- 0.6% to 7.4 +/- 0.8% (P < 0.0001). This evidence concerns the gene INS and type 2 diabetes mellitus.